Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Shares Outstanding (Diluted Average): 2020-2024

  • Pharming Group N.V's Shares Outstanding (Diluted Average) rose 19.51% to $785,511 in Q2 2024 from the same period last year, while for Jun 2024 it was $785,511, marking a year-over-year increase of 19.51%. This contributed to the annual value of $724,060 for FY2023, which is N/A change from last year.
  • As of Q2 2024, Pharming Group N.V's Shares Outstanding (Diluted Average) stood at $785,511, which was up 8.49% from $724,060 recorded in Q4 2023.
  • In the past 5 years, Pharming Group N.V's Shares Outstanding (Diluted Average) registered a high of $880,240 during Q4 2020, and its lowest value of $657,270 during Q2 2023.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $721,260, with a median of $721,128 in 2022.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first decreased by 8.48% in 2023, then climbed by 19.51% in 2024.
  • Over the past 5 years, Pharming Group N.V's Shares Outstanding (Diluted Average) (Quarterly) stood at $880,240 in 2020, then dropped by 0.95% to $871,838 in 2021, then fell by 5.76% to $718,197 in 2022, then fell by 8.48% to $724,060 in 2023, then rose by 19.51% to $785,511 in 2024.
  • Its last three reported values are $785,511 in Q2 2024, $724,060 for Q4 2023, and $657,270 during Q2 2023.